摘要
目的:观察奥拉西坦辅助治疗脑梗死患者的效果。方法:选取62例脑梗死患者作为研究对象,采用随机数字表法分为对照组和观察组各31例,对照组采用吡拉西坦辅助治疗,观察组采用奥拉西坦辅助治疗,比较两组认知障碍情况、临床疗效及不良反应发生情况。结果:治疗后,观察组简易智能精神状态检查量表评分明显高于对照组,差异有统计学意义(P<0.05);观察组治疗有效率为93.55%,明显高于对照组的74.19%,差异有统计学意义(P<0.05);观察组不良反应发生率为6.45%,明显低于对照组的29.03%,差异有统计学意义(P<0.05)。结论:奥拉西坦辅助治疗脑梗死患者,可改善患者的认知功能,提高治疗效果,降低不良反应发生率,效果优于吡拉西坦效果。
Objective: To explore effects of Oxiracetam adjuvant treatment on patients with cerebral infarction. Methods: 62 patients with cerebral infarction were selected as the research objects, and were divided into control group and observation group by using the random number table method, 31 cases in each. The control group was given Piracetam adjuvant treatment, while the observation group received Oxiracetam adjuvant treatment. Then, the cognitive impairments, clinical efficacy and adverse reactions were compared between the two groups. Results: After the treatment, the mini mental state examination score of the observation group was significantly higher than that of the control group, the difference was statistically significant(P<0.05). The effective rate in the observation group was 93.55%, which was significantly higher than 74.19% in the control group, and the difference was statistically significant(P<0.05). Further, the incidence of adverse reactions in the observation group was 6.45%, which was significantly lower than the control group of 29.03%, and the difference was statistically significant(P<0.05). Conclusions: Oxiracetam in the adjuvant treatment of the patients with cerebral infarction can improve the patients’ cognitive function, improve the treatment effects, and reduce the incidence of adverse reactions. Moreover, it is superior to Piracetam.
作者
王广强
WANG Guangqiang(st Department of Neurology of the People’s Hospital of Jiawang District,Xuzhou 221011 Jiangsu,China)
出处
《中国民康医学》
2020年第5期17-18,共2页
Medical Journal of Chinese People’s Health
